Dextroamphetamine as an Adjunct in Cocaine Treatment - 1
NCT ID: NCT00000304
Last Updated: 2017-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
120 participants
INTERVENTIONAL
1997-08-31
2001-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3
NCT00000306
Dextroamphetamine-Cocaine Behavioral Intervention - 5
NCT00000308
Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo
NCT00218348
Pilot Study Examining Effect for Dextroamphetamine to Treat Cocaine Dependence Plus Attention-deficit Hyperactivity Disorder (ADHD)
NCT00514202
Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer
NCT02383043
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
15/30 mg d-amphetamine
Dextroamphetamine
15 mg for first 8 weeks and 30 mg for 2nd 8 weeks
2
30/60 mg d-amphetamine
D-Amphetamine
30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)
3
placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dextroamphetamine
15 mg for first 8 weeks and 30 mg for 2nd 8 weeks
D-Amphetamine
30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Texas
OTHER
National Institute on Drug Abuse (NIDA)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Texas Medical School at Houston
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Grabowski, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Texas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas Health Science Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P50-09262-1
Identifier Type: -
Identifier Source: secondary_id
NIDA-09262-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.